Hence, studying activation/inactivation of the tumor-driving K-RAS/SIAH/EGFR pathway represents an opportunity to define therapy-responsive and prognostic K-RAS/SIAH-centered biomarkers in TNBC. The gene discussed is KRAS; the disease is neoplasm.